Searched over 200M research papers
10 papers analyzed
These studies suggest metformin generally prevents or reduces weight gain in various populations, including those with type 2 diabetes, pregnant women, and patients on antipsychotic medications.
16 papers analyzed
20 papers analyzed
Metformin is a widely used medication for managing type 2 diabetes, known for its ability to improve insulin sensitivity and glycemic control. However, its effects on body weight have been a subject of extensive research, particularly in the context of diabetes management, pregnancy, and antipsychotic-induced weight gain.
Research indicates that metformin can mitigate weight gain associated with insulin therapy in patients with type 2 diabetes. A study comparing insulin therapy alone to insulin combined with metformin found that while both groups experienced improved glycemic control, the metformin group had significantly less weight gain (3.8 kg vs. 7.5 kg). This suggests that metformin can help reduce the weight gain typically associated with insulin therapy by decreasing energy intake.
Another study explored the long-term effects of metformin on energy intake and weight gain in type 2 diabetes patients. Over a 4.3-year period, it was found that metformin users had significantly less weight gain compared to placebo users, despite no significant difference in energy intake between the groups. This indicates that metformin's weight-sparing effects may not be solely due to reduced energy intake.
Metformin has also been studied for its effects on weight gain during pregnancy. A retrospective cohort study found that pregnant women with type 2 diabetes or prediabetes who were exposed to metformin had less excess weight gain and a higher rate of weight loss compared to those not exposed to the drug. This suggests that metformin can help manage weight gain during pregnancy without adversely affecting fetal growth.
In obese pregnant women without diabetes, metformin was shown to reduce maternal gestational weight gain significantly compared to placebo (4.6 kg vs. 6.3 kg). This further supports the potential of metformin in managing weight gain during pregnancy, even in the absence of diabetes.
Metformin has been effective in managing weight gain in children and adolescents treated with second-generation antipsychotics (SGAs). A systematic review and meta-analysis found that metformin significantly reduced weight gain in this population. Another study confirmed that metformin stabilized weight in children and adolescents whose weight had increased significantly during antipsychotic therapy.
In adults with schizophrenia, metformin has been shown to attenuate weight gain induced by antipsychotic medications like olanzapine. A double-blind, placebo-controlled study found that patients treated with olanzapine and metformin had significantly less weight gain and better insulin sensitivity compared to those treated with olanzapine and placebo.
Overall, the evidence suggests that metformin does not cause weight gain. Instead, it appears to have weight-neutral or weight-sparing effects in various populations, including those with type 2 diabetes, pregnant women, and individuals taking antipsychotic medications. These findings highlight the potential of metformin as a valuable adjunct in managing weight gain associated with different medical conditions and treatments.
Most relevant research papers on this topic